Hermann Nabi, PhD, HDR, is a regular researcher in the Oncology division at CHU de Québec-Université Laval Research Center and Assistant Professor of Epidemiology at the Department of Social and Preventive Medicine at the Faculty of Medicine of Université Laval. Prior to joining the Center and Université Laval in 2016, Dr. Nabi headed the Research Department of Social and Human Sciences, Epidemiology, Public Health at the Institut National du Cancer(INCa) and was a regular researcher at l’Institut National de la Santé et de la Recherche Médicale(INSERM U.1018) in France.
His team’s work focuses on precision medicine, this emerging medical approach for disease prevention and treatment that takes into account individual differences in genes, environment and lifestyle for each person. With advances in genomics and the advent of new molecular biology technologies, precision medicine is attracting a lot of attention and has become an area of strong international competition. However, despite the large volume and unprecedented rate of gene or biomarker discoveries, relatively few have reached the bedside or contributed to improving the health of populations. This relative poor performance could be explained by the fact that only a small proportion (about 3%) of all published global research addresses issues related to the integration of genomics innovations into health and disease prevention. For this reason, the ultimate goal of Dr. Nabi’s team is to generate evidence to facilitate a successful and responsible integration of precision medicine innovations into health care and prevention, particularly for cancer.
To achieve this goal, his work is organized around three main objectives:
1) Characterize the mechanisms and organizational implications of the progressive adoption of innovations in precision medicine in oncology,
2) Evaluate the impact of diagnostic and therapeutic innovations in precision medicine on the quality of life and clinical outcomes of cancer patients and the effectiveness for the health system,
3) Develop and evaluate intervention methods to support the integration of innovations, which takes into account patients and populations’ preferences, economic, accessibility and impact issues, in a knowledge transfer perspective.
The originality of this research program lies in its interdisciplinary approach, which combines a variety of skills and methodological tools to answer questions that are at the interface of several scientific fields. This approach proposes a new way of approaching translational research (the transfer of discoveries from laboratory to bedside), through the use of concepts, models and methods the human and social sciences, epidemiology, public health, health services research and implementation science.
1050, Chemin Ste-Foy
Canada G1S 4L8
- Hermann Nabi sélectionné pour le Gairdner 2022 Early Career Investigator Lecture 2021-10-26
- [ULaval Nouvelles] Découvertes fortuites lors de tests génomiques: au patient de choisir 2021-03-23
- [Ulaval Nouvelles] Cancer du sein: les Canadiennes appuient fortement le dépistage adapté au risque personnel 2021-02-16
Issues associated with a hereditary risk of cancer: Knowledge, attitudes and practices of nurses in oncology settingsJournal Article
Can Oncol Nurs J, 32 (2), 2022.
Enjeux associés au risque héréditaire de cancer: connaissances, attitudes et pratiques infirmières en oncologieJournal Article
Can Oncol Nurs J, 32 (2), 2022.
Whether, when, how, and how much? General public's and cancer patients' views about the disclosure of genomic secondary findingsJournal Article
BMC Med Genomics, 14 (1), 2021.
Cross-Cultural Adaptation and Validation of a French Version of the Genetic Counseling Satisfaction Scale (GCSS) as an Outcome Measure of Genetic Counseling for Hereditary Breast and Ovarian CancerJournal Article
Healthcare (Basel), 9 (9), 2021.
Identifying Clinicopathological Factors Associated with Oncotype DX 21-Gene Recurrence Score: A Real-World Retrospective Cohort Study of Breast Cancer Patients in Quebec City, CanadaJournal Article
J Pers Med, 11 (9), 2021.
Should Age-Dependent Absolute Risk Thresholds Be Used for Risk Stratification in Risk-Stratified Breast Cancer Screening?Journal Article
J Pers Med, 11 (9), 2021.
Personalized Risk Assessment for Prevention and Early Detection of Breast Cancer: Integration and Implementation (PERSPECTIVE I&I)Journal Article
J Pers Med, 11 (6), 2021.
Risk-Stratified Approach to Breast Cancer Screening in Canada: Women's Knowledge of the Legislative Context and Concerns about Discrimination from Genetic and Other Predictive Health DataJournal Article
J Pers Med, 11 (8), 2021.
Theoretical conceptions of intervention research addressing cancer control issuesJournal Article
Health Promot Int, 36 (1), 2021.
A Collaborative Model to Implement Flexible, Accessible and Efficient Oncogenetic Services for Hereditary Breast and Ovarian Cancer: The C-MOnGene StudyJournal Article
Cancers (Basel), 13 (11), 2021.
- Enjeux de l’intégration de la Médecine de Précision en Oncologie : mieux comprendre pour mieux agir (teMPO), from 2018-07-01 to 2022-06-30
- Exploring the impact for COVID-19 pandemic on women with breast cancer in Quebec, from 2021-12-01 to 2023-09-30
- Personalized Risk Assesment for Prevention and Early Detection of Breast Cancer : Integration and Implementation (PERSPECTIVE II), from 2017-11-01 to 2024-03-31
- What are my options? A feasibility study of a personalized primary prevention strategy for women and men at high risk of breast and prostate cancer, from 2022-01-15 to 2023-01-14
Recently finished projects
- Conseil génétique concernant le risque héréditaire de cancer du sein: Comment améliorer l’offre de services pour préserver la qualité de vie et la satisfaction des femmes potentiellement à risque?, from 2019-01-01 to 2021-01-31
- Pilot study of a community pharmacy-based program to enhance adherence to adjuvant endocrine therapy among breast, from 2019-10-01 to 2022-02-28
- Programme de soutien aux nouveaux chercheurs, from 2018-07-01 to 2020-06-30
- Quand innovations technologique et organisationnelle vont de pair: Un modèle collaboratif pour rendre l'oncogénétique plus agile, accessible et efficiente, from 2020-04-01 to 2022-03-31